{"id":558758,"date":"2026-07-15T12:30:00","date_gmt":"2026-07-15T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=558758"},"modified":"2026-07-15T13:19:09","modified_gmt":"2026-07-15T11:19:09","slug":"sglt-2-inhibitors-and-glp-1-receptor-agonists-significant-improvement-in-renal-outcomes","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/sglt-2-inhibitors-and-glp-1-receptor-agonists-significant-improvement-in-renal-outcomes\/","title":{"rendered":"SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Approximately 30\u201340% of patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In \u201clandmark\u201d studies such as CREDENCE, DAPA-CKD, EMPA-KIDNEY, and several others,<em> SGLT-2 (sodium-glucose-linked transporter 2) inhibitors<\/em>demonstrated verifiable benefits in renal endpoints, and the FLOW study has since also demonstrated significant nephroprotective effects of a<em> GLP-1 (glucagon-like peptide-1)-RA<\/em>has also been shown to have significant nephroprotective effects in people with type 2 diabetes.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fsglt-2-inhibitors-and-glp-1-receptor-agonists-significant-improvement-in-renal-outcomes%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Approximately 30\u201340% of patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In \u201clandmark\u201d studies such as CREDENCE, DAPA-CKD, EMPA-KIDNEY, and several others, SGLT-2 (sodium-glucose-linked transporter 2)&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fsglt-2-inhibitors-and-glp-1-receptor-agonists-significant-improvement-in-renal-outcomes%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":558760,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11548,11508,11384,11297,11413,11503],"tags":[24174,12831,12821,94775,66543,23427,44110,94782,20717,65608,94778,94783,94780,18549,12042],"powerkit_post_featured":[],"class_list":["post-558758","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-education","category-endocrinology-and-diabetology","category-general-internal-medicine","category-nephrology","category-studies","tag-canagliflozin-en","tag-chronic-kidney-disease","tag-ckd-en","tag-credence","tag-dapa-ckd-en","tag-dapagliflozin-en","tag-empagliflozin-en","tag-flow-study","tag-forxiga-en","tag-glp-1-ra-en-2","tag-jardiance","tag-nephroprotective-effects","tag-ozempic","tag-sglt-2-i-en","tag-type-2-diabetes","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-31 06:13:58","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":558721,"slug":"sglt-2-i-et-glp-1-ra-amelioration-significative-des-criteres-devaluation-renaux","post_title":"SGLT-2-i et GLP-1-RA : am\u00e9lioration significative des crit\u00e8res d'\u00e9valuation r\u00e9naux","href":"https:\/\/medizinonline.com\/fr\/sglt-2-i-et-glp-1-ra-amelioration-significative-des-criteres-devaluation-renaux\/"},"it_IT":{"locale":"it_IT","id":558728,"slug":"sglt-2-i-e-glp-1-ra-miglioramento-significativo-degli-esiti-renali","post_title":"SGLT-2-i e GLP-1-RA: miglioramento significativo degli esiti renali","href":"https:\/\/medizinonline.com\/it\/sglt-2-i-e-glp-1-ra-miglioramento-significativo-degli-esiti-renali\/"},"pt_PT":{"locale":"pt_PT","id":558765,"slug":"sglt-2-i-e-glp-1-ra-melhoria-significativa-nos-parametros-renais","post_title":"SGLT-2-i e GLP-1-RA: melhoria significativa nos par\u00e2metros renais","href":"https:\/\/medizinonline.com\/pt-pt\/sglt-2-i-e-glp-1-ra-melhoria-significativa-nos-parametros-renais\/"},"es_ES":{"locale":"es_ES","id":558772,"slug":"inhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales","post_title":"Inhibidores de SGLT-2 y agonistas selectivos del GLP-1: mejora significativa de los criterios de valoraci\u00f3n renales","href":"https:\/\/medizinonline.com\/es\/inhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/558758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=558758"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/558758\/revisions"}],"predecessor-version":[{"id":561391,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/558758\/revisions\/561391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/558760"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=558758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=558758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=558758"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=558758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}